

IN THE CLAIMS

Please cancel claims 15, and 21, amend claims 16, 19, 20 and 22 and add new claims 33-35 as follows:

1-14. (WITHDRAWN)

15. (CANCELLED)

Q1 16. (CURRENTLY AMENDED) The method of claim 45 ~~33~~, wherein the first insulin species is human insulin and the second insulin species is a variant of human insulin having at least one amino acid substitution.

17. (ORIGINAL) The method of claim 16, wherein the variant of human insulin is LISPRO insulin.

18. (ORIGINAL) The method of claim 17, wherein the human insulin comprises from about 1% to about 50% of the insulin of the composition and wherein the LISPRO insulin comprises from about 50% to about 99% of the insulin of the composition.

Q2 19. (CURRENTLY AMENDED) The method of claim 18 ~~42~~, wherein the human insulin comprises from about 5% to about 20% of the insulin of the composition and wherein the LISPRO insulin comprises from about 95% to about 80% of the insulin of the composition.

20. (CURRENTLY AMENDED) The method of claim 45 ~~33~~, wherein the composition is a pharmaceutical composition.

21. (CANCELLED)

Q3 22. (CURRENTLY AMENDED) The method of claim 34 ~~24~~, wherein the first insulin species is human insulin and the second insulin species is a variant of human insulin having at least one amino acid substitution.

23. (ORIGINAL) The method of claim 22, wherein the variant of human insulin is LISPRO insulin.

24. (ORIGINAL) The method of claim 23, wherein the human insulin comprises from about 1% to about 50% of the insulin of the composition and wherein the LISPRO insulin comprises from about 50% to about 99% of the insulin of the composition.

25. (ORIGINAL) The method of claim 24, wherein the human insulin comprises from about 5% to about 20% of the insulin of the composition and wherein the LISPRO insulin comprises from about 95% to about 80% of the insulin of the composition.

26. (ORIGINAL) The method of claim 25, wherein the composition is a pharmaceutical composition.

27-32. (WITHDRAWN)

ay 33. (NEW) A method of making an insulin heterodimer composition, the method comprising:

- (a) selecting a first insulin species and a second insulin species;
- (b) adding the first insulin species and the second insulin species together in a <sup>an</sup> aqueous solution comprising a pharmaceutically acceptable carrier;
- (c) allowing the first insulin species and the second insulin species to associate in the solution so that the insulin heterodimer composition is made;

wherein the first insulin species and the second insulin species are selected so that the heterodimer formed by the first insulin species and the second insulin species is more stable than a homodimer formed by the first insulin species or a homodimer formed by the second insulin species.

34. (NEW) A method of stabilizing an insulin composition comprising:

- (a) selecting a first insulin species and a second insulin species, wherein the first insulin species and the second insulin species are selected such that a heterodimer formed by the first

insulin species and the second insulin species is more stable than a homodimer formed by the first insulin species or a homodimer formed by the second insulin species;

(b) adding the first insulin species and the second insulin species together in a aqueous solution comprising a pharmaceutically acceptable carrier;

(c) allowing the first insulin species and the second insulin species to associate in the solution so that a insulin heterodimer is formed by the first insulin species and the second insulin species; so that the insulin composition is stabilized.

35. (NEW) A method of making an insulin heterodimer composition, the method comprising:

(a) adding human insulin and LISPRO insulin together in an aqueous solution comprising a pharmaceutically acceptable carrier;

(b) allowing the human insulin and LISPRO insulin to associate in the solution so that the insulin heterodimer composition is made;

wherein the human insulin and LISPRO insulin are selected so that a heterodimer formed by the human insulin and LISPRO insulin is more stable than a homodimer formed by the human insulin or a homodimer formed by the LISPRO insulin.

---